Microbot Medical Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Harel Gadot
- Full Time Employees
- 43
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 175 Derby Street Hingham MA United States of America 02043
- IPO Date
- Mar 25, 1992
- CIK
- 0000883975
- Website
- microbotmedical.com
- Similar Companies
- Business
- Microbot Medical Inc. is an innovative medical technology firm focused on transforming endovascular procedures through advanced robotic systems. The company primarily engineers sophisticated micro-robotic devices for minimally invasive interventions within the human body's natural and artificial lumens. Its flagship offering, the LIBERTY® Endovascular Robotic System, represents the first FDA-cleared, single-use, remotely operated robotic solution specifically designed for peripheral endovascular procedures. This system aims to enhance precision and safety while significantly reducing radiation exposure for clinical staff and mitigating physical strain. Microbot Medical’s portfolio also includes the NovaCross™ Microcatheter family, acquired in 2022, which can be utilized independently or integrated with the LIBERTY system for specialized procedural kits. The company continues to advance other proprietary platforms, such as the Self-Cleaning Shunt (SCS) technology, intended for treating hydrocephalus and normal pressure hydrocephalus. Following its FDA 510(k) clearance in September 2025, the LIBERTY system commenced a limited market release in the U.S. in the fourth quarter of 2025, with plans for a broader commercial launch in April 2026. A strategic collaboration with Stryker Corporation’s Neurovascular division is ongoing, focusing on integrating neurovascular instruments with the LIBERTY system to develop dedicated robotic kits for specific neurovascular operations. The company maintains a robust intellectual property portfolio, expanding its global patent coverage with recent grants in Japan, complementing existing patents in the U.S., China, and Israel. Microbot Medical Inc. was established in 2010 and operates from Hingham, Massachusetts.
Company News
Financial Analysis: Koninklijke Philips (NYSE:PHG) & Microbot Medical (NASDAQ:MBOT)
Microbot Medical Inc. (MBOT) Reports Q2 Loss, Lags Revenue Estimates
Microbot Medical® Files 10-Q, Reports Significant Revenue and Customer Growth During the 2026 Second Quarter
New Strong Buy Stocks for July 23rd
Microbot Medical® Among Featured Companies Showcasing Novel Robotic Technologies and Digital Surgery Applications at the Society of Robotic Surgery Annual Meeting
Microbot Medical® Reports Over 100% Revenue and Customer Growth as Procedure Volume Also Rises in the Second Quarter of 2026
Microbot Medical® Increases Manufacturing Capacity as Demand for the LIBERTY® System Rises; Enters into Strategic Agreement with Sanmina, a Global Manufacturing Leader
Microbot Medical® Wins Surgical Robotics Industry Award for the LIBERTY® Endovascular Robotic System
Microbot Medical® Announces First Health System in Pennsylvania to Adopt the LIBERTY® Endovascular Robotic System
Microbot Medical® Enters Into an Agreement to Expand Access for America's Veteran and Military Patient Populations
Microbot Medical® Announces a Notable Health System as the First in Michigan to Adopt the LIBERTY® Endovascular Robotic System
Microbot Medical® Secures the First Healthcare System in North Carolina to Adopt the LIBERTY® Endovascular Robotic System
Microbot Medical® Receives Its First International Regulatory Approval for the Commercialization of the LIBERTY® Endovascular Robotic System
After Plunging 22.6% in 4 Weeks, Here's Why the Trend Might Reverse for Microbot Medical (MBOT)
Microbot Medical Inc. (MBOT) Shareholder/Analyst Call Transcript
Microbot Medical to Hold Analysts and Investors Conference Call to Review Recent Progress; Executive Team will be Joined by Current Users of the LIBERTY Endovascular Robotic System, Dr. Charles Briggs and Dr. Zachary Bercu
Microbot Medical Successfully Transitions to Commercial Operations as It Records Revenue Resulting from Its Limited Market Release During the First Quarter of 2026
Microbot Medical Inc. (MBOT) Reports Q1 Loss, Misses Revenue Estimates
Microbot Medical®'s LIBERTY® Endovascular Robotic System is Now Adopted by Multiple Accounts Across Key Territories Including Two ACCESS-PVI Pivotal Clinical Trial Sites
Microbot Medical® Announces the Addition of Senior Commercial Executive with Proven Track Record to Accelerate Commercial Readiness in Europe, the Middle East, and Asia (EMEA)